NCT02629029 is a NA clinical trial of Pre-op CTA with IV contrast in Head and Neck Neoplasms, sponsored by University Health Network, Toronto.

Who is sponsoring NCT02629029?

NCT02629029 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT02629029?

Interventions in NCT02629029: Pre-op CTA with IV contrast, Computed tomography angiography (CTA).

What condition does NCT02629029 study?

NCT02629029 studies Head and Neck Neoplasms.

Is NCT02629029 still recruiting?

NCT02629029 is currently terminated. Last updated 16 December 2020.

Last reviewed 2020-12-16 · How we verify

NCT02629029

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-Modality Imaging for Head & Neck Cancer Free Flap Design Assessment

Terminated NA Last updated 16 December 2020

What this trial tests

NA trial testing Pre-op CTA with IV contrast in Head and Neck Neoplasms in 4 participants. Terminated before completion.

Timeline

30 May 2015

Primary endpoint
27 November 2020

27 November 2020

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	4
Start date	30 May 2015
Primary completion	27 November 2020
Estimated completion	27 November 2020
Sites	1 location across Canada

Drugs / interventions tested

Pre-op CTA with IV contrast
Computed tomography angiography (CTA)

Conditions studied

Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Head and Neck Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Surgical reconstruction of anatomical structures after head and neck cancer resection has made enormous strides in the past 20 years with advancing flap techniques and the usage of perforating vessels, but accurate and consistent identification of these perforators has remained a challenge due to the varying anatomy of vasculature in the donor region. Computed tomography angiography (CTA) has been used increasingly in preoperative free flap perforator mapping for breast reconstruction but has been limited in head and neck applications. In addition, indocyanine green (ICG) assisted NIR fluorescence angiography has been developed for intra-operative flap assessment. In this study, the investigators propose to assess a previously undocumented, multi-modal imaging technique with preoperative dual energy CTA to design and intraoperative ICG assisted NIR angiography to assess free flap in head and neck reconstruction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation.
Olson MT, Ly QP, Mohs AM. · · 2019 · cited 48× · PMID 29942988 · DOI 10.1007/s11307-018-1239-2

Verify or expand the search:

Other recruiting trials for Head and Neck Neoplasms

Currently open trials in the same condition.

NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
NCT06998069 — Head and Neck Cancer Study Project in the Geriatric Population · Phase 3 · recruiting
NCT07158164 — DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment · Phase 4 · recruiting
NCT06303180 — NIDCD Otolaryngology Clinical Protocol Biospecimen Bank · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02629029 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 16 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02629029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing